Positive Results for BioLineRx Heart Attack Treatment

biline.jpgBioLineRx, an Israeli drug development company, has announced that the first heart attack patient has emerged unscathed from a Phase 1/2 clinical trial study of its BL-1040, a breakthrough approach to supporting damaged cardiac tissue. The trial is using up to 30 patients in several sites in Germany, Belgium and Israel and is designed to assess the safety and feasibility of the treatment which BioLineRx is hoping to have approved as a Class III Medical Device.

According to the press release, BL-1040, which was shown in pre-clinical trials performed on animals to improve survival rates, is “a resorbable liquid polymer that is administered via the coronary artery during standard catheterization and flows into the damaged heart muscle. The liquid polymerizes within the infarcted cardiac tissue and forms a protective “scaffold” that enhances the mechanical strength of the heart muscle during recovery and repair, thereby preventing pathological enlargement of the left ventricle after the MI. BL-1040 is excreted naturally from the body within six weeks after injection, leaving behind a stronger, more stable heart muscle.”

Morris C. Laster, MD, CEO of BioLineRx said that this “is an important milestone in the development of BL-1040, BioLineRx’s innovative product candidate, which is the first treatment that attempts to treat damaged cardiac tissue resulting from an acute MI and addresses a tremendous unmet medical need.”

Professor Jonathan Leor, co-inventor of BL-1040, added that it “could revolutionize the treatment of patients recovering from a massive heart attack” and that he believes further trials “will continue to provide more evidence for the success of our new approach to bring effective and safe treatment for patients with injured hearts.”

BioLineRx, whose BL-1020 treatment for Schizophrenia is about to begin Phase 2b clinical trials in U.S., Europe and Israel, was founded in 2003 by members of Israel’s life science community including Teva Pharmaceuticals Ltd. with help from Giza Venture Capital, Pitango Venture Capital, and Hadasit.

Check out the full press release for more info.


One Response

  1. Acute MI is a leading cause of morbidity and mortality in the Western world. Approximately 1.3 million cases of nonfatal MI are reported each year in the U.S. alone, with an annual incidence rate of approximately 600 cases per 100,000 people.
    BL-1040 if it is safe and efficacious will be a breakthrough approach to support cardiac tissue damaged as a result of acute myocardial infarction (MI)
    The first patient with the first was treated recently with BL-1040 was released from the Department of Cardiology at the University of Heidelberg in Germany following treatment with no apparent adverse effects. .Congratulation to BioLineRx Ltd. (TASE:BLRX).
    Raj Nihalani, MD, RAC(US)

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: